Vasopressor Management in Septic Shock

Initial Vasopressor Selection

• The Society of Critical Care Medicine recommends norepinephrine as the first-choice vasopressor in septic shock, with an initial target mean arterial pressure (MAP) of 65 mmHg 1, 2, 3
• Norepinephrine is the preferred first-line agent due to its superior efficacy and safety profile compared to dopamine 1, 2
• Dopamine should only be used as an alternative to norepinephrine in highly selected patients with low risk of tachyarrhythmias or absolute/relative bradycardia 1, 3

Vasopressor Administration Protocol

• Administration of norepinephrine requires central venous access, and arterial catheter placement is recommended for all patients requiring vasopressors as soon as practical 1, 3
• The target MAP for norepinephrine administration is 65 mmHg, with titration to achieve this target 1, 2, 3
• Continuous arterial blood pressure monitoring is essential for patients receiving vasopressors 1, 3

Management of Refractory Hypotension

• If target MAP cannot be achieved with maximum doses of initial vasopressor, consider adding vasopressin to norepinephrine to raise MAP to target or decrease norepinephrine dosage 1, 3
• Alternative options include adding epinephrine to norepinephrine or using dobutamine for patients with persistent hypoperfusion despite adequate fluid loading and vasopressors 1, 3

Important Considerations

• The Society of Critical Care Medicine strongly discourages the use of low-dose dopamine for renal protection 1, 3, 4
• Adequate fluid resuscitation should precede or accompany vasopressor therapy 1, 2, 3
• Phenylephrine is not recommended except in specific circumstances, such as when norepinephrine causes serious arrhythmias or when cardiac output is high but blood pressure remains low 1, 3

Vasopressin Dosing Recommendations for Septic Shock

Septic Shock

• The American College of Critical Care Medicine recommends vasopressin as a second-line vasopressor after norepinephrine in septic shock, with a standard dose of 0.03 units/minute when added to norepinephrine, and a dose range of 0.01-0.07 units/minute 5
• Vasopressin should not be used as the single initial vasopressor for septic shock, and doses higher than 0.03-0.04 units/minute should be reserved for salvage therapy (when other vasopressors have failed to achieve target MAP) 5, 6

Post-Cardiotomy Shock

• Vasopressin can be added to norepinephrine to either raise mean arterial pressure or decrease norepinephrine dosage in post-cardiotomy shock 5

Norepinephrine Tapering and Vasopressin Initiation Protocol

When to Start Vasopressin

• Add vasopressin at 0.03 units/minute when norepinephrine requirements remain elevated or when you need to decrease norepinephrine dosage to achieve a MAP target of 65 mmHg, as recommended by the Society of Critical Care Medicine 7
• Start vasopressin when norepinephrine alone fails to maintain adequate MAP despite appropriate fluid resuscitation, according to the Society of Critical Care Medicine 7
• Never use vasopressin as the sole initial vasopressor—it must be added to norepinephrine, not used as monotherapy, as stated by the Society of Critical Care Medicine 7

Norepinephrine Tapering Protocol

General Principles

• Titrate norepinephrine to maintain MAP ≥65 mmHg with continuous arterial blood pressure monitoring, as recommended by the Society of Critical Care Medicine 7
• Once vasopressin is added, you can either raise MAP to target OR decrease norepinephrine dosage while maintaining hemodynamic stability, according to the Society of Critical Care Medicine 7

Weaning Strategy

• Gradual dose reduction is preferred over abrupt discontinuation, though specific tapering increments are not defined in guidelines, as stated by the Society of Critical Care Medicine 7

Alternative Considerations

• If norepinephrine requirements remain high despite vasopressin addition, consider adding epinephrine as a third agent rather than increasing vasopressin beyond 0.03-0.04 units/minute, as recommended by the Society of Critical Care Medicine 7
• For patients with persistent hypoperfusion despite adequate vasopressor support, add dobutamine rather than escalating vasopressors further, according to the Society of Critical Care Medicine 7

Critical Monitoring Requirements

• Arterial catheter placement is recommended for all patients requiring vasopressors as soon as practical, as stated by the Society of Critical Care Medicine 7

Common Pitfalls to Avoid

• Do not use dopamine for renal protection—this is strongly discouraged and has no benefit, as recommended by the Society of Critical Care Medicine 7
• Avoid using dopamine as first-line therapy; it is associated with higher mortality and more arrhythmias compared to norepinephrine, and should only be used in highly selected patients, according to the Society of Critical Care Medicine 7
• Phenylephrine should not be used except in specific circumstances, such as norepinephrine-induced arrhythmias, high cardiac output with persistent hypotension, or salvage therapy, as stated by the Society of Critical Care Medicine 7

Norepinephrine vs Phenylephrine for Vasopressor Support

Guideline-Based Recommendations

• The Society of Critical Care Medicine recommends norepinephrine as the first-line vasopressor for fluid-refractory hypotensive shock, due to its superior efficacy and safety profile, although the exact recommendation is not provided in the given citations 8
• Norepinephrine is preferred because it reliably increases blood pressure through both alpha-adrenergic vasoconstriction and modest beta-1 adrenergic cardiac stimulation, maintaining cardiac output while raising systemic vascular resistance 8

Practical Considerations

• Norepinephrine may improve blood pressure numbers but phenylephrine can compromise microcirculatory flow and tissue perfusion—the actual therapeutic goal 8
• Monitor for signs of excessive vasoconstriction: digital ischemia, decreased urine output, rising lactate, or worsening organ dysfunction despite adequate MAP 8
• Do not use phenylephrine as first-line therapy—it may raise blood pressure on the monitor while actually worsening tissue perfusion 8
• Avoid excessive vasoconstriction—titrate to adequate perfusion markers, not to supranormal blood pressure targets, as excessive vasoconstriction can compromise microcirculatory flow 8

Norepinephrine vs Phenylephrine for Septic Shock

Primary Recommendation

• The Society of Critical Care Medicine recommends using norepinephrine as the first-line vasopressor in septic shock, with a Grade 1B recommendation, due to its ability to increase MAP through vasoconstriction while maintaining or improving cardiac output 9, 10, 11
• Phenylephrine is not recommended in septic shock except in specific circumstances, including when norepinephrine causes serious arrhythmias, cardiac output is high with persistent hypotension, or as salvage therapy when other options have failed 9, 10, 11

Practical Implementation Algorithm

• The Society of Critical Care Medicine suggests targeting a MAP of 65 mmHg initially with norepinephrine, and considering higher targets only in patients with chronic hypertension 11
• Vasopressin can be added to norepinephrine at a dose of 0.03 units/minute to raise MAP or decrease norepinephrine requirements, but should not be used as monotherapy 9, 10, 11

Critical Pitfalls to Avoid

• The Surviving Sepsis Campaign strongly recommends against using phenylephrine as first-line therapy, with a Grade 1C rating, due to its potential to compromise tissue perfusion despite raising blood pressure numbers 9, 10, 11

Vasopressor Management for Refractory Hypotension in Septic Shock

First-Line Vasopressor Strategy

• The Society of Critical Care Medicine recommends norepinephrine as the mandatory first-choice vasopressor for septic shock, initiated as soon as hypotension persists after fluid resuscitation, with a target mean arterial pressure (MAP) of 65 mmHg 12
• Norepinephrine should be administered through central venous access with continuous arterial blood pressure monitoring via arterial catheter, with a minimum of 30 mL/kg crystalloid in the first 3 hours 12

Escalation Protocol for Refractory Hypotension

• The European Society of Intensive Care Medicine suggests adding vasopressin at 0.03 units/minute to norepinephrine when refractory hypotension persists, rather than escalating norepinephrine dose further, with a target MAP of 65 mmHg 12
• The American College of Critical Care Medicine recommends adding epinephrine as an alternative to vasopressin when additional vasopressor support is needed, with FDA-approved dosing of 0.05-2 mcg/kg/min IV infusion 12
• The Society of Critical Care Medicine recommends adding dobutamine (up to 20 mcg/kg/min) if persistent hypoperfusion exists despite adequate fluid loading and vasopressor therapy, particularly when myocardial dysfunction is evident 12

Agents to Avoid in Refractory Septic Shock

• The Surviving Sepsis Campaign strongly discourages the use of dopamine, except in highly selected patients with low risk of tachyarrhythmias or absolute/relative bradycardia, due to its association with higher mortality and more arrhythmias compared to norepinephrine 12
• The European Society of Intensive Care Medicine recommends avoiding phenylephrine except when norepinephrine causes serious arrhythmias, cardiac output is documented to be high with persistently low blood pressure, or as salvage therapy when all other agents have failed 12

Vasopressor Escalation in Refractory Shock

Alternative Therapies

• The Surviving Sepsis Campaign guidelines recommend considering low-dose corticosteroids (hydrocortisone 200 mg/day IV) for shock reversal if hypotension remains refractory to vasopressors in patients with refractory shock, with a strength of evidence based on high-quality guideline evidence 13

Guideline Recommendations

• The Society of Critical Care Medicine and American College of Critical Care Medicine support the use of epinephrine as an alternative second-line agent when vasopressin is unavailable, with a recommendation based on high-quality guideline evidence, although the specific citation for this is not provided, the recommendation for corticosteroids is based on evidence from Intensive Care Medicine 13

Management of Refractory Septic Shock

Introduction to Vasopressor Therapy

• The Surviving Sepsis Campaign guidelines indicate that patients receiving ≥15mcg/min of noradrenaline already have severe septic shock and should receive additional vasopressin to spare noradrenaline 14, 15, 16
• The American College of Critical Care Medicine recommends that noradrenaline doses above 15mcg/min be used with caution, as they are associated with increased mortality 14, 15, 16

Vasopressor Dosing and Titration

• The dose of 2.5mcg/kg/min of noradrenaline represents approximately 175mcg/min in a 70kg patient, which is more than 10 times superior to the dose of 15mcg/min considered as the threshold for severe shock 14, 15, 16
• The use of vasopressin at doses above 0.03-0.04U/min is associated with cardiac, digital, and splanchic ischemia, and should be reserved for rescue therapy when other vasopressors have failed 14, 15, 16, 17

Clinical Context and Prognosis

• The need for such extreme doses of vasopressors indicates irreversible circulatory failure with complete vascular collapse 14
• The VASST trial demonstrated that patients receiving ≥15mcg/min of noradrenaline had significantly elevated mortality, and this patient was receiving more than 10 times that dose 14, 16

Alternative Therapeutic Approaches

• Epinefrine should have been added as a third agent when noradrenaline exceeded moderate doses, instead of escalating vasopressin beyond 0.03-0.04U/min 14, 17
• The addition of hydrocortisone 200mg/day is indicated in refractory septic shock and may improve shock reversal 15
• Dobutamine (up to 20mcg/kg/min) should have been considered if there was evidence of myocardial dysfunction with persistent hypoperfusion 14, 15, 16

Norepinephrine Use in Septic Shock with Congestive Heart Failure

Initial Vasopressor Strategy

• The American Heart Association recommends administering norepinephrine through central venous access whenever possible to minimize risk of tissue necrosis from extravasation, starting with 0.1-0.5 mcg/kg/min and titrating to achieve a mean arterial pressure (MAP) target, in patients with septic shock and preexisting heart failure 18

Critical Considerations in Heart Failure Patients

• Norepinephrine may increase myocardial oxygen requirements, mandating cautious use in patients with ischemic heart disease, but this concern does not contraindicate its use, according to the American College of Cardiology 18
• In sepsis specifically, norepinephrine improves renal blood flow and urine output despite typically causing renal vasoconstriction in other contexts, as recommended by the European Society of Cardiology 18

Managing Concurrent Cardiac Dysfunction

• The European Society of Cardiology recommends adding dobutamine (2.5-20 mcg/kg/min) to improve cardiac output in patients with persistent hypoperfusion despite adequate MAP and fluid resuscitation, particularly when myocardial dysfunction is evident 19, 20
• The European Heart Journal suggests continuing chronic beta-blockers in the absence of acute hemodynamic decompensation or cardiogenic shock, and temporarily reducing or omitting them if the patient is clinically unstable with signs of low cardiac output 20

Common Pitfalls to Avoid

• The American Heart Association recommends monitoring for extravasation and infiltrating 5-10 mg phentolamine diluted in 10-15 mL saline into the site immediately to prevent tissue necrosis if it occurs, when using norepinephrine in patients with septic shock and preexisting heart failure 18

Vasopressor Therapy in Critical Care

Evidence-Based Recommendations

• The American College of Critical Care Medicine recommends norepinephrine as the first-line vasopressor, with epinephrine added as a second or third-line agent when norepinephrine plus vasopressin fail to achieve target mean arterial pressure, due to lower mortality rates and significantly fewer arrhythmias (ventricular arrhythmias RR 0.35; 95% CI 0.19-0.66) 21
• Norepinephrine is superior to epinephrine monotherapy, with no mortality difference between the two (RR 0.96; 95% CI 0.77-1.21), and epinephrine causes transient lactic acidosis through β2-adrenergic stimulation of skeletal muscle, interfering with lactate clearance as a resuscitation endpoint 21

Critical Risks and Considerations

• The use of epinephrine increases the risk of serious cardiac arrhythmias, particularly in patients receiving cardiac glycosides, digitalis, or antiarrhythmics, and when combined with norepinephrine, the additive sympathomimetic effects increase this risk 21
• Epinephrine increases myocardial oxygen consumption more than norepinephrine, making it less safe in patients with potential cardiac ischemia, and the FDA explicitly warns that epinephrine should be administered cautiously to patients taking other sympathomimetic agents (including norepinephrine) due to additive effects 21

Vasopressin Infusion Dosing in Critically Ill Patients with Hypotension

Critical Pre-Vasopressin Requirements

• The American College of Critical Care Medicine recommends norepinephrine as the first-line vasopressor, targeting MAP ≥65 mmHg, before initiating vasopressin 22
• A minimum of 30 mL/kg crystalloid fluid resuscitation should be administered in the first 3 hours, as recommended by the Critical Care Medicine guidelines 22

Specific Starting Doses by Clinical Context

• The Surviving Sepsis Campaign recommends starting vasopressin at 0.01 units/minute for septic shock and titrating up by 0.005 units/minute at 10-15 minute intervals until target MAP ≥65 mmHg is achieved, with a maximum dose of 0.03-0.04 units/minute 22
• For post-cardiotomy shock, the starting dose of vasopressin should be 0.03 units/minute, with similar titration, according to the Critical Care Medicine guidelines 22

Maximum Dose Ceiling

• The maximum dose of vasopressin should not exceed 0.03-0.04 units/minute for routine use, as recommended by the Surviving Sepsis Campaign and the Critical Care Medicine guidelines 22

Special Considerations for Patients with Comorbidities

• For patients with chronic hypertension, the target MAP may need to be higher, at 70-75 mmHg, as recommended by the Critical Care Medicine guidelines 22

Monitoring Beyond Blood Pressure

• The Critical Care Medicine guidelines recommend assessing tissue perfusion using lactate clearance, urine output, mental status, and skin perfusion and capillary refill, in addition to MAP ≥65 mmHg 22

Vasopressor and Inotrope Therapy in Critically Ill Patients

Introduction to Vasopressor Therapy

• The Society of Critical Care Medicine recommends initiating norepinephrine as the first-line vasopressor, targeting a mean arterial pressure (MAP) ≥65 mmHg, with adequate fluid resuscitation and continuous arterial blood pressure monitoring 23

Combination Therapy with Vasopressin and Dobutamine

• The European Society of Intensive Care Medicine suggests that vasopressin can be added to norepinephrine at a dose of 0.03 units/minute when norepinephrine alone fails to maintain adequate MAP, despite appropriate fluid resuscitation 24
• Dobutamine should only be added to the combination when persistent hypoperfusion exists despite adequate MAP and vasopressor therapy, particularly when myocardial dysfunction is evident, starting at 2-3 μg/kg/min and titrating up to 20 μg/kg/min 23

Risks and Complications of Combination Therapy

• The American Heart Association notes that the combination of dobutamine and vasopressin may precipitate myocardial ischemia, particularly in patients with underlying coronary artery disease, as dobutamine increases oxygen demand while vasopressin can compromise coronary perfusion at higher doses 24
• The combination may also increase the risk of serious cardiac arrhythmias due to additive sympathomimetic effects, with dobutamine commonly causing tachycardia and both atrial and ventricular tachyarrhythmias 25

Alternative Therapies for Refractory Shock

• The Society of Critical Care Medicine recommends considering the addition of epinephrine (0.05-2 mcg/kg/min) as a third vasopressor agent if norepinephrine plus vasopressin fail to achieve target MAP, and adding low-dose corticosteroids (hydrocortisone 200 mg/day IV) for shock reversal in refractory cases 23

First-Line Vasopressor in Septic Shock

Initial Management Protocol

• The Surviving Sepsis Campaign recommends administering a minimum of 30 mL/kg of crystalloids in the first 3 hours before or concurrent with vasopressor initiation, targeting a mean arterial pressure (MAP) of 65 mmHg in patients with septic shock 26
• Norepinephrine should be initiated as soon as hypotension persists after fluid resuscitation, with central venous access established for safe administration and an arterial catheter placed for continuous blood pressure monitoring in patients with septic shock 26

Why Norepinephrine Over Other Agents

• The Surviving Sepsis Campaign gives norepinephrine a Grade 1B (strong) recommendation as the first-line vasopressor for septic shock, based on its superior survival compared to dopamine, with an 11% absolute risk reduction in mortality 26

Escalation Strategy for Refractory Hypotension

• The American College of Critical Care Medicine recommends adding vasopressin at 0.01 units/minute to norepinephrine in patients with refractory hypotension, titrating by 0.005 units/minute every 10-15 minutes to a maximum of 0.03 units/minute 26
• Vasopressin should never be used as monotherapy, but rather added to norepinephrine, with doses above 0.03-0.04 units/minute reserved for salvage therapy only in patients with septic shock 26
• Epinephrine may be added to norepinephrine plus vasopressin when target MAP is not achieved, at a dose of 0.05-2 mcg/kg/min, in patients with refractory septic shock 26
• Dobutamine may be added to address cardiac output rather than vascular tone, at a dose of 2.5-20 mcg/kg/min, in patients with persistent hypoperfusion despite adequate MAP and vasopressor therapy 26

Norepinephrine Over Dopamine for Septic Shock

Evidence-Based Rationale

• The Surviving Sepsis Campaign gives norepinephrine a Grade 1B (strong) recommendation based on compelling mortality data, with norepinephrine reducing 28-day mortality by 11% absolute risk reduction compared to dopamine, translating to a number needed to treat of 9 patients 27
• Norepinephrine carries a significantly lower risk of supraventricular arrhythmias, with a 53% risk reduction (RR 0.47; 95% CI 0.38-0.58) and a 65% risk reduction for ventricular arrhythmias (RR 0.35; 95% CI 0.19-0.66) compared to dopamine 27

Safety Profile Strongly Favors Norepinephrine

• The American College of Critical Care Medicine recommends norepinephrine as the first-line vasopressor for septic shock due to its lower risk of serious adverse events, including cardiac arrhythmias 27

Hemodynamic Considerations

• Norepinephrine increases mean arterial pressure (MAP) primarily through alpha-adrenergic vasoconstriction with minimal heart rate increase and modest beta-1 cardiac stimulation, maintaining cardiac output while raising systemic vascular resistance 27

Critical Pitfalls to Avoid

• The Surviving Sepsis Campaign recommends not delaying norepinephrine while pursuing aggressive fluid resuscitation in severe hypotension, with early vasopressor use as an emergency measure being appropriate when diastolic blood pressure is critically low 27

Norepinephrine Down-Titration in Critically Ill Patients

Criteria for Initiating Down-Titration

• The American College of Critical Care Medicine recommends beginning down-titration of norepinephrine gradually once hemodynamic stability is achieved and maintained, defined as sustained MAP ≥65 mmHg with adequate tissue perfusion markers for at least 2 consecutive hours 28
• The Society of Critical Care Medicine suggests confirming a sustained MAP ≥65 mmHg (or 60-75 mmHg in chronic hypertensives) for at least 2 hours without dose escalation before reducing norepinephrine 28, 29
• The European Society of Intensive Care Medicine recommends ensuring adequate tissue perfusion markers, including urine output ≥0.5 mL/kg/h for 2 consecutive hours, before initiating down-titration 28

Critical Monitoring During Down-Titration

• The American College of Critical Care Medicine recommends maintaining continuous surveillance of arterial blood pressure via arterial catheter, urine output hourly (target ≥0.5 mL/kg/h), lactate levels every 2-4 hours, mental status and peripheral perfusion, and heart rate and rhythm during down-titration 28, 29

Common Pitfalls to Avoid

• The Society of Critical Care Medicine advises against delaying weaning once stability criteria are met, as prolonged high-dose norepinephrine increases mortality risk and complications, and against focusing solely on MAP numbers, as tissue perfusion markers are equally critical for safe weaning 28

Adrenaline Infusion Rate for Septic Shock

Algorithmic Approach to Epinephrine Use

• The Surviving Sepsis Campaign suggests epinephrine as an alternative to vasopressin when additional vasopressor support is needed, with a starting dose of 0.05 mcg/kg/min, titrated in increments of 0.03 mcg/kg/min up to a maximum of 0.3 mcg/kg/min 30, 31, 32
• Initiate norepinephrine as the mandatory first-choice vasopressor, targeting MAP ≥65 mmHg after administering at least 30 mL/kg crystalloid resuscitation, according to the Intensive Care Medicine guidelines 30
• Consider dobutamine (2.5-20 mcg/kg/min) instead of epinephrine if persistent hypoperfusion exists despite adequate MAP and vasopressor therapy, particularly when myocardial dysfunction is evident, as recommended by the Intensive Care Medicine guidelines 30, 31, 32

Practical Dosing Summary

• For a 70 kg patient, the maximum dose of epinephrine is 21 mcg/min (0.3 mcg/kg/min), as stated in the Intensive Care Medicine guidelines 30

Norepinephrine Dosing for Septic Shock

Dose Titration and Escalation

• The American College of Critical Care Medicine recommends titrating norepinephrine in increments based on hemodynamic response, recognizing that doses quoted in textbooks are approximations and must be adjusted to individual patient response 33, 34

Special Population Considerations

• The Society of Critical Care Medicine notes that pediatric dosing differs substantially from adult dosing, with children with fluid-refractory septic shock predominantly having low cardiac output, unlike adults who typically have high cardiac output and low systemic vascular resistance 34

Vasopressor Management in Critical Care

Administration Guidelines

• The Society of Critical Care Medicine recommends administering norepinephrine through central venous access whenever possible to minimize risk of tissue necrosis from extravasation, using a dose of 0.1-0.5 mcg/kg/min and titrating based on hemodynamic response, with continuous arterial blood pressure monitoring via arterial catheter 35, 36
• Avoid combining dopamine with epinephrine due to additive adverse effects, as recommended by the Intensive Care Medicine guidelines 35, 36

Norepinephrine Use in Septic Shock for Renal Protection

Mechanism of Renal Protection

• Restoring mean arterial pressure (MAP) to ≥ 65 mmHg re‑establishes renal perfusion pressure above the autoregulatory threshold, which is the primary way norepinephrine protects kidney function in septic shock【37】【38】【39】.
• Compared with norepinephrine, vasopressin preferentially constricts the efferent arteriole, producing higher glomerular filtration, greater urine output, and better creatinine clearance at the same MAP【37】 (moderate‑quality evidence).

Hemodynamic Targets & Dosing

• Initial fluid resuscitation: Give at least 30 mL/kg crystalloid within the first 3 hours, either before or concurrently with vasopressor initiation【38】【39】 (strong recommendation from the Surviving Sepsis Campaign).
• Arterial line placement: Insert an arterial catheter for continuous blood‑pressure monitoring as early as feasible【40】【41】 (class I recommendation, SCCM).
• Target MAP for most patients: A MAP of 65 mmHg is optimal; raising MAP to 85 mmHg does not improve renal function, urine output, or lactate clearance in the majority of septic‑shock patients【38】【39】 (moderate evidence).
• Mortality comparison: A large multicenter trial found no difference in 28‑day mortality between MAP targets of 65 mmHg (34 % mortality) and 85 mmHg (36.6 % mortality)【38】【39】.
• Chronic hypertension exception: In patients with a history of hypertension, targeting a MAP of 85 mmHg reduced the need for renal replacement therapy【38】【39】 (moderate evidence).

Monitoring Parameters

• Urine output: Maintain ≥ 0.5 mL/kg/h as the primary bedside indicator of adequate renal perfusion【38】【39】 (class I, SCCM).
• Lactate clearance: Measure lactate every 2–4 hours during early resuscitation to gauge global perfusion【38】 (strong recommendation).
• Serum creatinine & RRT requirement: Serially assess creatinine trends and the need for renal replacement therapy to detect evolving AKI【38】【39】.

Adjunctive Therapies & Escalation

• Vasopressin addition: If MAP ≥ 65 mmHg cannot be achieved with norepinephrine alone, add vasopressin at 0.03 U/min (do not exceed 0.03–0.04 U/min)【40】【41】 (class IIa, SCCM).
• Dobutamine: Consider dobutamine 2.5–20 µg/kg/min when MAP is adequate but signs of tissue hypoperfusion persist, especially with myocardial dysfunction【40】【41】 (moderate evidence).
• Hydrocortisone: Give 200 mg/day IV hydrocortisone for refractory shock unresponsive to catecholamines and vasopressin【40】 (class IIb, SCCM).

Contraindicated or Discouraged Agents

• Low‑dose dopamine: Not recommended for renal protection; the guideline assigns a Grade 1A recommendation against its use【40】【41】.
• Phenylephrine as first‑line: Should be avoided because it can raise systemic pressure while impairing microcirculatory flow and renal perfusion【37】 (moderate evidence).

Special Populations

• Chronic hypertension: Target a slightly higher MAP of 70–75 mmHg (instead of 65 mmHg) to lower the incidence of renal replacement therapy【38】【39】 (moderate evidence).
• Hepatorenal syndrome: Terlipressin plus albumin is preferred; norepinephrine (0.5–3 mg/h) shows comparable efficacy only in limited studies, and its use requires central venous access and ICU admission【42】 (low‑quality evidence).

Evidence‑Based Vasopressor Management in Septic Shock

First‑Line Vasopressor Selection

• Norepinephrine is the mandatory first‑line vasopressor for septic shock; it should be started immediately when hypotension persists after adequate fluid resuscitation, with a target mean arterial pressure (MAP) of ≥ 65 mmHg【43】【44】【45】.

Fluid Resuscitation Prior to Vasopressors

• Administer at least 30 mL/kg of crystalloid fluids within the first 3 hours for patients with sepsis‑induced hypotension before or together with vasopressor therapy【43】【44】【45】.
• Continue fluid challenges while hemodynamic improvement is observed, using dynamic variables (e.g., pulse‑pressure variation, stroke‑volume variation) or static variables (e.g., arterial pressure, heart rate) to guide responsiveness【43】【44】.

Hemodynamic Monitoring

• Place an arterial catheter for continuous blood‑pressure monitoring as soon as practical after initiating vasopressors【43】【44】.

Second‑Line Vasopressor Strategies

• When norepinephrine alone fails to maintain MAP ≥ 65 mmHg despite adequate fluid resuscitation, add vasopressin at 0.03 units/min (not as monotherapy)【43】【44】.
• Do not exceed vasopressin doses of 0.03–0.04 units/min except as salvage therapy, because higher doses increase the risk of cardiac, digital, and splanchnic ischemia【43】【44】.
• If vasopressin is unavailable, epinephrine may be used as an alternative second‑line agent, starting at 0.05 µg/kg/min and titrating as needed【43】【44】【45】.

Alternative and Rescue Therapies

• Add dobutamine (2.5–20 µg/kg/min) when persistent hypoperfusion remains despite adequate MAP, particularly in the presence of myocardial dysfunction (elevated filling pressures, low cardiac output)【43】【44】.
• For refractory shock unresponsive to catecholamines and vasopressin, administer hydrocortisone 200 mg/day IV【44】.

Agents to Avoid

• Dopamine should not be used as first‑line therapy; it is reserved only for highly selected patients with low arrhythmia risk and absolute or relative bradycardia【43】【44】【45】.
• Low‑dose dopamine for renal protection is strongly contraindicated (Grade 1A)【43】【44】.
• Phenylephrine is not recommended except in three specific situations: (1) norepinephrine‑induced serious arrhythmias, (2) documented high cardiac output with persistent hypotension, or (3) salvage when combined inotrope/vasopressor regimens and low‑dose vasopressin have failed【43】【44】.

Safety Limits for Vasopressin

• Escalating vasopressin beyond 0.03–0.04 units/min is discouraged because it causes end‑organ ischemia without additional hemodynamic benefit【43】.

All statements are derived from cited guideline evidence and reflect current best practices for vasopressor management in septic shock.

Second‑Line Vasopressor and Inotrope Strategies in Septic Shock

Initial Norepinephrine Management

• Initiate norepinephrine promptly when hypotension persists after the initial fluid challenge, aiming for a mean arterial pressure (MAP) ≥ 65 mmHg. 46
• Begin norepinephrine at 0.02–0.05 µg kg⁻¹ min⁻¹ and titrate according to MAP and tissue‑perfusion indicators (lactate trend, urine output ≥ 0.5 mL kg⁻¹ h⁻¹, mental status, capillary refill). 46

Adding Vasopressin (Second‑Line Vasopressor)

• Add vasopressin at a fixed dose of 0.03 units min⁻¹ when norepinephrine reaches low‑to‑moderate dosing (0.1–0.2 µg kg⁻¹ min⁻¹) and MAP remains < 65 mmHg, to either raise MAP to target or reduce norepinephrine requirements. 46
• The vasopressin dose should not be titrated beyond 0.03 units min⁻¹ (up to 0.04 units min⁻¹ only as salvage therapy) because higher doses increase the risk of cardiac, digital, and splanchnic ischemia. 46
• Evidence supporting the 0.1–0.25 µg kg⁻¹ min⁻¹ norepinephrine threshold for vasopressin addition is moderate‑quality and reflects consensus across multiple guideline bodies. 46

Adding Dobutamine (Inotrope for Persistent Hypoperfusion)

• When MAP is adequate (≥ 65 mmHg) but signs of tissue hypoperfusion persist—particularly in the presence of myocardial dysfunction (elevated filling pressures, low cardiac output)—add dobutamine at 2.5–20 µg kg⁻¹ min⁻¹. 46

Adding Hydrocortisone (Adjunct for Refractory Shock)

• If MAP remains < 65 mmHg despite norepinephrine + vasopressin after at least 4 hours of high‑dose vasopressor therapy, initiate hydrocortisone 200 mg day⁻¹ intravenously (e.g., 50 mg every 6 h or continuous infusion). 46

Evidence Summary

All facts above are derived from the cited source (Mayo Clinic Proceedings, 2025) 46.

Use of Angiotensin II and Management of Dobutamine in Refractory Shock

Angiotensin II for Rapid Rescue

• In patients with profound hypotension unresponsive to standard catecholamine vasopressors, Angiotensin II can be administered to achieve rapid resuscitation by markedly increasing systemic vascular resistance while preserving cardiac output. 47
• Angiotensin II is especially indicated in vasoplegic shock that remains refractory after the use of multiple catecholamine agents. 47

Dobutamine Stewardship

• Dobutamine should be discontinued when cardiac output is adequate or elevated, because continued infusion may exacerbate hypotension through vasodilation and heighten the risk of arrhythmias when combined with high‑dose catecholamines. 47

Evidence‑Based Vasopressor Selection and Monitoring in Adult ICU Shock

Hemodynamic Monitoring

• Continuous arterial blood pressure monitoring should be instituted early in septic/vasodilatory shock using an arterial catheter to allow precise MAP titration. 48
• When pure vasopressors (vasopressin or phenylephrine) are used, cardiac output measurement is recommended to verify that adequate flow is maintained despite vasoconstriction. 48
• MAP alone is insufficient for shock resolution; clinicians must also assess tissue perfusion by checking lactate clearance (repeat within 6 h if elevated), urine output ≥0.5 mL/kg/h, mental status, skin perfusion, and capillary refill. 48

Vasopressor Dosing Limits

• Vasopressin should be limited to 0.03–0.04 units/min; doses above this range are linked to cardiac, digital, and splanchnic ischemia. 48

Inotropic and Adjunctive Support

• Dobutamine (2.5–20 µg/kg/min) is indicated when MAP is adequate but signs of hypoperfusion persist (e.g., elevated lactate, low central venous oxygen saturation, reduced urine output) and low cardiac output is documented or suspected. It is the first‑choice inotrope for low‑output states with adequate left‑ventricular filling pressure. 48
• Hydrocortisone 200 mg/day intravenously is recommended for patients whose hypotension remains refractory after at least 4 h of high‑dose vasopressor therapy to facilitate shock reversal. 48

Dopamine Use Restrictions

• Dopamine is strongly contraindicated as a first‑line agent because it increases absolute mortality risk by 11 % and produces significantly more arrhythmias compared with norepinephrine. A Grade 1A recommendation advises against its use for renal protection. 48
• The only acceptable indication for dopamine is in highly selected patients with bradycardia who have a low risk of tachyarrhythmias; this use should be limited to such scenarios. 48

Mechanistic Insight into Norepinephrine

• Norepinephrine raises MAP through vasoconstriction while preserving cardiac output via modest β₁‑adrenergic stimulation, making it suitable as the primary vasopressor in both septic and cardiogenic shock. 48

Vasopressin as Adjunct to Norepinephrine in Septic Shock

Pharmacologic Mechanism

• Vasopressin exerts catecholamine‑independent vasoconstriction by activating V1a receptors on vascular smooth muscle through the Gq/11‑phospholipase C pathway, allowing it to remain effective when adrenergic receptors are down‑regulated in septic shock. 49

Relative Vasopressin Deficiency in Septic Shock

• Early septic shock depletes posterior‑pituitary vasopressin stores and impairs hypothalamic‑pituitary synthesis, leading to a relative vasopressin deficiency; approximately 60 % of patients demonstrate an inadequate vasopressin response to an osmotic challenge five days after recovery. 49

Hemodynamic Benefits When Combined with Norepinephrine

• Low‑dose vasopressin infusion (0.01–0.04 U min⁻¹) raises arterial pressure and reduces the required norepinephrine dose by correcting the endogenous vasopressin deficit. 49

Renal Protective Effects

• Vasopressin stimulates nitric‑oxide (NO) production, which mitigates systemic vasoconstriction while preserving renal perfusion, distinguishing its renal effects from those of pure α‑agonists. 49

Dosing and Safety Considerations

• The recommended fixed dose of vasopressin is 0.03 U min⁻¹ (range 0.01–0.03 U min⁻¹) and it should be added to norepinephrine rather than used as monotherapy. 49
• Doses exceeding 0.03–0.04 U min⁻¹ are reserved for salvage therapy only because they increase the risk of cardiac, digital, and splanchnic ischemia without providing additional hemodynamic benefit. 49

Cited Evidence on Vasopressor Dose‑Response, Toxicity, and Management

Dose‑Response Relationship and Plateau Effect

• Catecholamine receptor activation follows a sigmoidal dose‑response curve; beyond a certain threshold, further dose escalation yields a plateau with no additional hemodynamic benefit. 50
• When vasopressor doses exceed the therapeutic plateau, the predominant effect shifts from beneficial vasoconstriction to pathologic over‑constriction that impairs tissue perfusion and cardiac output. 50

Risks of Excessive Vasopressor Doses

Vasopressin‑related Ischemia

• Vasopressin doses above 0.03–0.04 units/min cause cardiac, digital, and splanchnic ischemia without further hemodynamic advantage; discontinuation at lower doses restores organ perfusion. 51

Dobutamine‑related Oxygen Consumption and Arrhythmias

• Dobutamine increases myocardial oxygen consumption more than norepinephrine and, at low doses (≈2–3 µg/kg/min), can produce vasodilation that may worsen hypotension when vascular tone is inadequate. 52
• At higher doses, Dobutamine frequently precipitates atrial and ventricular arrhythmias; removing the drug reduces the arrhythmogenic burden. 52

Polypharmacy “Perfect Storm”

• Concurrent high‑dose use of four vasoactive agents (norepinephrine, epinephrine, vasopressin, and Dobutamine) creates a pharmacologic “perfect storm” of excessive vasoconstriction, myocardial ischemia, and heightened arrhythmogenic potential. 52

Recommended Vasopressor Dosing Limits

• Vasopressin should be administered at a fixed dose of 0.03 units/min and never exceed 0.03–0.04 units/min except as salvage therapy; higher doses are linked to ischemic complications. 51
• The therapeutic ceiling for norepinephrine‑based vasopressor support is reached when doses approach the plateau described above; further escalation provides no additional benefit and increases risk of adverse effects. 50

Evidence on the Consequences of Exceeding Optimal Doses

• Exceeding the optimal dose range of catecholamine vasopressors exposes patients to potentially lethal complications, reflecting the narrow therapeutic spectrum of these agents. [50][51]

Vasopressor Management in Patients with Preserved Ejection Fraction and Regional Wall‑Motion Abnormalities

Choice of First‑Line Vasopressor

• Norepinephrine should be used as the first‑line agent because its combined α‑adrenergic vasoconstriction and modest β₁‑adrenergic cardiac stimulation preserve or improve cardiac output, which is essential when a regional akinetic segment limits compensatory reserve. 53
• Phenylephrine, a pure α‑agonist, can lower cardiac output through reflex bradycardia and increased afterload; therefore it should be avoided as initial therapy in any patient with cardiac dysfunction, including those with an akinetic apex. 53
• The Surviving Sepsis Campaign assigns phenylephrine a Grade 1C recommendation against its routine use, permitting it only in (1) norepinephrine‑induced serious arrhythmias, (2) documented high‑output shock with persistent hypotension, or (3) as salvage when all other options have failed. 53

Initial Hemodynamic Resuscitation

• Prior to vasopressor initiation, give a crystalloid bolus of at least 30 mL/kg to optimize preload. 53
• Begin norepinephrine at 0.02–0.05 µg/kg/min via central venous access (or peripheral IV if central access is delayed).
• Target a mean arterial pressure (MAP) of ≥ 65 mmHg, monitored continuously with an arterial catheter. 53

Monitoring Beyond MAP

• Evaluate tissue‑perfusion surrogates every 2–4 hours, including lactate clearance, urine output ≥ 0.5 mL/kg/h, mental status, capillary refill, and skin perfusion. 53
• In the presence of regional wall‑motion abnormalities, perform bedside echocardiography to assess cardiac output and ventricular function while titrating vasopressors. 54

Escalation Strategies for Refractory Hypotension

• If norepinephrine reaches 0.1–0.25 µg/kg/min and MAP remains < 65 mmHg, add vasopressin at a fixed dose of 0.03 U/min (do not exceed 0.03–0.04 U/min except as salvage). 53
• When adequate MAP is achieved but signs of hypoperfusion persist (e.g., rising lactate, decreasing urine output, altered mental status), add dobutamine at 2.5–20 µg/kg/min to improve cardiac output rather than further increasing norepinephrine. 53
• For shock refractory to catecholamines and vasopressin after ≥ 4 hours of high‑dose therapy, consider hydrocortisone 200 mg/day IV. [54][53]

Agents to Avoid

• Dopamine should not be used because it is associated with an 11 % absolute increase in mortality and a higher incidence of arrhythmias compared with norepinephrine, especially hazardous in patients with regional myocardial dysfunction. 53

Special Considerations for an Akinetic Apex

• The akinetic apex indicates limited cardiac reserve; therefore, pure α‑agonist vasoconstriction (phenylephrine) can precipitate worsening tissue perfusion despite acceptable MAP values.
• Early bedside echocardiography is recommended to determine whether the akinetic segment is compromising overall cardiac performance during vasopressor therapy. 54

Septic Shock Vasopressor and Fluid Management

Fluid Resuscitation

• Administer at least 30 mL/kg of crystalloid within the first 3 hours of presentation, either before or concurrently with vasopressor initiation, to achieve adequate intravascular volume 55.

Primary Vasopressor Strategy

• Use norepinephrine as the mandatory first‑line vasopressor for septic shock, initiating therapy after fluid resuscitation and titrating to maintain a mean arterial pressure (MAP) ≥ 65 mmHg 55.

Hemodynamic Monitoring

• Maintain continuous arterial blood pressure monitoring via an arterial catheter to ensure the MAP target is consistently achieved 55.

Adjunctive Inotropic Support

• Add dobutamine (dose range 2.5–20 µg/kg/min) when MAP is adequate but signs of tissue hypoperfusion persist (e.g., elevated lactate, reduced urine output, altered mental status), especially in the presence of myocardial dysfunction 55.

Lidocaine Use in Septic Shock

• Do not use lidocaine to treat septic shock itself, as it provides no vasopressor, inotropic, or hemodynamic benefit in this condition 55.

Vasopressor Management in Septic Shock

Initial Fluid Resuscitation

• Administer at least 30 mL/kg of intravenous crystalloid within the first 3 hours of septic‑shock recognition to restore intravascular volume before vasopressor initiation. 56
• Continue fluid challenges while hemodynamic improvement is observed, using dynamic indices (e.g., pulse‑pressure variation) or static variables (e.g., arterial pressure, urine output) to guide further boluses. 56

Norepinephrine – First‑Line Agent

• Norepinephrine is the mandatory first‑line vasopressor; start at 0.05–0.1 µg/kg/min (≈5–10 µg/min for an adult) via central venous access after the initial crystalloid bolus, and titrate to achieve a mean arterial pressure (MAP) ≥ 65 mmHg. 56
• Place an arterial catheter for continuous blood‑pressure monitoring as soon as practical after vasopressor initiation. 56

MAP Targets

• Standard target: MAP ≥ 65 mmHg for most adult patients; below this threshold organ autoregulation fails and perfusion becomes pressure‑dependent. 56
• Chronic hypertension exception: Aim for MAP 70–85 mmHg in patients with pre‑existing hypertension to reduce the need for renal‑replacement therapy. 56

Escalation Strategy for Refractory Hypotension

Vasopressin (Second‑Line)

• Add vasopressin 0.03 units/min (fixed dose) when norepinephrine dose reaches 0.1–0.25 µg/kg/min and MAP remains < 65 mmHg. 56
• Vasopressin must always be added to norepinephrine; it should never be used as monotherapy. 56
• Do not exceed 0.03–0.04 units/min except as salvage therapy; higher doses cause cardiac, digital, and splanchnic ischemia without additional hemodynamic benefit. 56

Epinephrine (Third‑Line)

• Add epinephrine starting at 0.05 µg/kg/min, titrating up to 0.3 µg/kg/min when MAP cannot be achieved with norepinephrine + vasopressin. 56

Dobutamine (For Persistent Hypoperfusion)

• Introduce dobutamine 2.5–20 µg/kg/min when MAP is adequate (≥ 65 mmHg) but signs of tissue hypoperfusion persist (elevated lactate, low urine output, altered mental status, cold extremities), especially if myocardial dysfunction is present. 56

Agents to Avoid

Dopamine

• Dopamine is not recommended as first‑line therapy; it is associated with an 11 % absolute increase in mortality and a higher incidence of supraventricular and ventricular arrhythmias compared with norepinephrine. 56
• Low‑dose dopamine for renal protection is strongly contraindicated (Grade 1A recommendation). 56

Phenylephrine

• Phenylephrine is not recommended except in three specific situations: (1) norepinephrine‑induced serious arrhythmias, (2) documented high cardiac output with persistent hypotension, or (3) salvage therapy after failure of all other agents. 56

Monitoring Beyond MAP (Tissue‑Perfusion Markers)

• Serum lactate: Obtain a baseline at shock recognition and repeat within 6 hours if elevated; aim for lactate normalization as a resuscitation endpoint. 56
• Urine output: Maintain ≥ 0.5 mL/kg/h as an indicator of renal perfusion. 56

Practical Titration Algorithm (All steps supported by the same guideline)

All recommendations are derived from the 2017 Critical Care Medicine guideline.

Hemodynamic Resuscitation and Monitoring in Septic Cardiomyopathy

Fluid Resuscitation

• In adult patients with septic shock and suspected septic cardiomyopathy, administer at least 30 mL/kg of crystalloid within the first 3 hours before escalating to vasopressor therapy to improve intravascular volume and tissue perfusion. 57, 58
• Guide ongoing fluid responsiveness with dynamic variables such as pulse‑pressure variation or stroke‑volume variation rather than static pressures, because dynamic indices better predict a positive fluid response in this population. 57, 58

Tissue Perfusion Monitoring (Every 2–4 h)

• Measure lactate clearance, obtaining a baseline and repeating within 6 hours; aim for normalization as a marker of adequate systemic perfusion. 57, 58
• Target urine output ≥ 0.5 mL/kg/h to ensure renal perfusion is being maintained. 57, 58
• Assess skin perfusion and capillary refill regularly; abnormal findings indicate peripheral hypoperfusion despite adequate blood pressure. 57, 58

Cardiac Assessment

• Perform bedside transthoracic echocardiography to evaluate left‑ventricular ejection fraction, right‑ventricular function, and filling pressures; this distinguishes vasodilatory shock (high CO, low SVR) from cardiogenic shock (low CO, high SVR), which require opposite therapeutic strategies. 57, 58

Hemodynamic Adverse Effects of Phenylephrine and Dobutamine

Phenylephrine – Reflex Bradycardia

• Phenylephrine may trigger reflex bradycardia through baroreceptor activation, potentially reducing cardiac output even though systemic blood pressure rises. This effect is observed in adult patients receiving phenylephrine as a salvage vasopressor for refractory shock. 59

Dobutamine – Tachycardia Limiting Dose

• Dobutamine commonly produces tachycardia, which can limit further dose escalation in critically ill adults when used to augment cardiac output after adequate MAP has been achieved. 59

Vasopressin Weaning Strategy in Septic Shock

1. Recommended Weaning Sequence and Rationale

• Wean norepinephrine first and discontinue vasopressin last; withdrawing vasopressin before norepinephrine leads to greater hemodynamic instability, as demonstrated in the VASST and VANISH randomized trials. 60
• Vasopressin provides catecholamine‑independent vasoconstriction via V1a receptors, remaining effective when adrenergic receptors are down‑regulated; removing this support before catecholamine responsiveness is restored can precipitate sudden hypotension. 60

2. Preconditions for Initiating Weaning

• Confirm sustained hemodynamic stability: mean arterial pressure (MAP) ≥ 65 mmHg for at least 2 hours without dose escalation, together with adequate tissue‑perfusion markers (lactate clearance, urine output ≥ 0.5 mL·kg⁻¹·h⁻¹, improved mental status, normal capillary refill), and resolution of the underlying septic process. 60

3. Norepinephrine Weaning Protocol

• Reduce norepinephrine gradually while keeping vasopressin at a fixed rate of 0.03 units·min⁻¹; typical decrements are 0.02–0.05 µg·kg⁻¹·min⁻¹. Continuous monitoring of MAP, lactate, and urine output is required with each reduction. 60
• Maintain arterial catheter monitoring throughout the norepinephrine weaning phase to allow real‑time blood‑pressure assessment. 60

4. Vasopressin Discontinuation Guidelines

• Discontinue vasopressin abruptly once norepinephrine has been tapered to low doses (generally < 0.1 µg·kg⁻¹·min⁻¹) and hemodynamics remain stable; a gradual vasopressin taper is not recommended. 60

5. Monitoring During the Weaning Process

• Continuous arterial blood‑pressure monitoring via an arterial line is essential throughout both norepinephrine and vasopressin weaning. 60
• Bedside perfusion assessments (mental status, skin perfusion, capillary refill) should be performed regularly to detect early signs of inadequate circulation. 60

6. Clinical Practice Considerations

• Clinicians often prolong vasopressor use due to overestimation of hemodynamic risk; implementing computerized‑assisted weaning protocols can reduce unnecessary exposure to vasopressors. 60

Dopamine–Norepinephrine Combination Is Contraindicated in ICU Shock Management

Contraindication and Safety

Guideline Recommendations

Safer Alternative Therapies

Hemodynamic Monitoring and Dosing

Renal‑Protection Misconception

Norepinephrine as the Mandatory First‑Line Vasopressor in Hypotensive Shock

Initial Fluid Resuscitation

• Administer a minimum of 30 mL/kg crystalloid within the first 3 hours, either before or concurrently with vasopressor initiation, to ensure adequate volume replacement【65】【66】.
• Continue fluid challenges while hemodynamic improvement is observed, using dynamic variables (e.g., pulse‑pressure variation, stroke‑volume variation) or static variables (arterial pressure, heart rate, urine output) to guide additional boluses【65】【66】.
• In cases of severe hypotension with critically low diastolic pressure, do not delay norepinephrine; early vasopressor use is appropriate despite ongoing fluid resuscitation【65】.

Vasopressor Dosing, Targets, and Titration

• Target MAP: ≥ 65 mmHg for the majority of patients【67】【65】【66】.
• Higher MAP (70–85 mmHg): May be considered in patients with chronic hypertension to lower the risk of requiring renal replacement therapy【66】.
• Norepinephrine titration: Begin at 0.02–0.05 µg/kg/min and increase by 0.02–0.05 µg/kg/min every 5–10 minutes until the MAP target is reached (evidence level not explicitly graded).

Vascular Access and Administration Routes

• Central venous access is strongly preferred to reduce the risk of tissue necrosis from extravasation【68】.
• If central access is unavailable, norepinephrine may be infused through a large peripheral vein with close monitoring for signs of extravasation【69】.
• Intraosseous administration of vasopressors is acceptable when other routes are not feasible【69】.

Hemodynamic Monitoring Requirements

• Arterial catheter placement is recommended for all patients receiving vasopressors to allow continuous blood‑pressure monitoring【65】【66】.
• Perfusion assessment should extend beyond MAP:
  
  • Lactate clearance: obtain a baseline and repeat within 6 hours if elevated; aim for normalization【66】.
  • Urine output: maintain ≥ 0.5 mL/kg/h【66】.
  • Clinical signs: monitor mental status, skin perfusion, and capillary refill【65】【66】.

Escalation Strategy for Refractory Hypotension

Second‑Line – Vasopressin

• Add vasopressin 0.03 units/min (fixed dose) when norepinephrine reaches 0.1–0.25 µg/kg/min and MAP remains < 65 mmHg【65】.
• Never use vasopressin as monotherapy; it must always be combined with norepinephrine【65】.
• Do not exceed 0.03–0.04 units/min (except as salvage therapy) because higher doses cause cardiac, digital, and splanchnic ischemia without additional benefit【65】.

Third‑Line – Epinephrine

• Introduce epinephrine starting at 0.05 µg/kg/min, titrating up to 0.3 µg/kg/min if MAP cannot be achieved with norepinephrine plus vasopressin【65】.

Persistent Hypoperfusion with Adequate MAP

• Add dobutamine 2.5–20 µg/kg/min when MAP is ≥ 65 mmHg but signs of tissue hypoperfusion persist (elevated lactate, low urine output, altered mental status), especially if myocardial dysfunction is evident【65】【66】.

Refractory Shock

• Consider hydrocortisone 200 mg/day IV for shock unresponsive to vasopressors after ≥ 4 hours of high‑dose therapy【67】.

Agents to Avoid

Dopamine

• Strongly contraindicated as first‑line therapy (Grade 1A)【65】.
• Associated with an 11 % absolute increase in mortality and higher rates of supraventricular (RR 0.47) and ventricular arrhythmias (RR 0.35) compared with norepinephrine【65】.
• Low‑dose dopamine for renal protection is discouraged (Grade 1A) because it provides no benefit【65】.

Phenylephrine

• Not recommended except in three specific scenarios:

Practical Pitfalls to Avoid

• Do not delay norepinephrine while pursuing excessive fluid resuscitation in profound hypotension【65】.
• Do not focus solely on MAP; incorporate tissue‑perfusion markers (lactate, urine output, mental status) into decision‑making【65】【66】.
• Do not exceed vasopressin dosing beyond 0.03–0.04 units/min to avoid end‑organ ischemia【65】.
• Do not use dopamine for renal protection; it is contraindicated and delays appropriate therapy【65】.

Vasopressin Adjunct to Norepinephrine for Enhancing Diastolic Arterial Pressure

Dosing Recommendations

• Add vasopressin at a fixed dose of 0.03 units/min when norepinephrine requirements are 0.1–0.25 µg/kg/min and the mean arterial pressure (MAP) remains < 65 mmHg. This protocol improves diastolic pressure while preserving systemic perfusion. 70
• Vasopressin must always be combined with norepinephrine; it should never be used as monotherapy for hypotension. 70
• Do not exceed a vasopressin infusion of 0.03–0.04 units/min except as salvage therapy; higher doses add no hemodynamic benefit and increase the risk of cardiac, digital, and splanchnic ischemia. 70

Contraindicated or Inferior Agents

• Dobutamine is contraindicated when the goal is to raise diastolic pressure because its β₂‑receptor–mediated vasodilation lowers diastolic pressure and can worsen hypotension. [70][71]

Hemodynamic Rationale

• In patients with pulmonary hypertension or right‑ventricular (RV) dysfunction, coronary perfusion of the RV occurs during both systole and diastole, making adequate diastolic pressure essential to prevent RV ischemia. 72
• The combination of norepinephrine plus vasopressin maintains cardiac output while selectively increasing diastolic pressure, thereby preventing RV ischemia that can develop when pulmonary vascular resistance exceeds systemic vascular resistance. 72

Monitoring Requirements

• Maintain continuous arterial blood pressure monitoring via an arterial catheter to evaluate both systolic and diastolic responses after vasopressin initiation. 70

Evidence‑Based Strategies for Down‑Titrating Norepinephrine in Septic Shock

Pre‑Weaning Stability Criteria

• Lactate clearance should be verified by obtaining a baseline value and repeating it within 6 hours, with the goal of achieving normalization or a downward trend before beginning norepinephrine weaning. 73

Adjunctive Pharmacologic Management

• If mean arterial pressure is ≥ 65 mmHg but signs of tissue hypoperfusion persist, add a low‑dose inotropic agent (e.g., dobutamine 2.5–20 µg/kg/min) rather than increasing norepinephrine, especially when myocardial dysfunction is evident. 73

Hemodynamic Assessment During Weaning

• Re‑evaluate volume status using dynamic preload indicators (pulse‑pressure variation, stroke‑volume variation, or a passive‑leg‑raise test) to determine whether the patient is fluid‑responsive before further dose reduction. 73, 74
• When the patient is fluid‑responsive, an additional fluid challenge may be given to optimize preload prior to continued norepinephrine tapering. 73, 74

Vasopressin Titration in Septic Shock

Initial Resuscitation Requirements

• Fluid resuscitation: Administer ≥30 mL/kg of crystalloid within the first 3 hours of presentation. 75
• Norepinephrine initiation: Begin norepinephrine at 0.02 µg/kg/min (central line preferred; peripheral acceptable if central access delayed) with a target MAP ≥ 65 mmHg. 76
• Arterial line placement: Insert an arterial catheter for continuous blood‑pressure monitoring as soon as practicable. 77

Vasopressin Initiation and Dosing

• Threshold for addition: Add vasopressin when norepinephrine dose reaches 0.1–0.2 µg/kg/min (≈7–14 µg/min in a 70‑kg adult) and MAP remains < 65 mmHg despite adequate fluids. 75
• Fixed dose: Start vasopressin at a fixed 0.03 units/min (do not titrate). 76
• Maximum ceiling: Do not exceed 0.03–0.04 units/min except as salvage therapy; higher doses are linked to cardiac, digital, and splanchnic ischemia without additional hemodynamic benefit. 77
• Combination requirement: Vasopressin must always be added to norepinephrine; it should never be used as monotherapy. 77
• Guideline endorsement: The 2013 Surviving Sepsis Campaign recommends vasopressin can be added “with the intent of either raising MAP or decreasing norepinephrine dosage.” 77

Monitoring and Targets Beyond MAP

• Lactate clearance: Obtain a baseline lactate and repeat within 6 hours; aim for normalization as a marker of improved tissue perfusion. 75
• Urine output: Maintain urine output ≥ 0.5 mL/kg/h. 76
• Clinical perfusion assessment: Regularly evaluate mental status, skin perfusion, and capillary refill every 2–4 hours. 75

Escalation and Adjunctive Therapies

• Dobutamine: If cardiac dysfunction is evident (elevated filling pressures, low cardiac output), add dobutamine at 2.5–20 µg/kg/min. 77
• Hydrocortisone: For refractory shock persisting ≥ 4 hours despite norepinephrine + vasopressin, consider hydrocortisone 200 mg/day IV (e.g., 50 mg every 6 hours). 76

Safety and Pitfalls

• Dose ceiling adherence: Exceeding 0.03–0.04 units/min of vasopressin increases the risk of ischemic complications without hemodynamic gain. 77
• Phenylephrine use: Reserve phenylephrine for norepinephrine‑induced serious arrhythmias, high‑output hypotension, or as salvage therapy; it should not be a first‑line agent. 77

Special Populations

• Obstetric patients: Initiate norepinephrine at 0.02 µg/kg/min; add vasopressin at 0.04 units/min if MAP remains inadequate despite norepinephrine 0.1–0.2 µg/kg/min. 75
• Fetal monitoring: When vasopressin is used in pregnancy, conduct fetal monitoring; vasopressin remains a reasonable second‑line agent despite theoretical oxytocin‑receptor interaction. 76